Skip to main content
Robin Joyce, MD, Oncology, Boston, MA, Beth Israel Deaconess Medical Center

RobinJoyceMDM.Div, MSc

Oncology Boston, MA

Hematologic Oncology

Director of Clinical Lymphoma Program

Dr. Joyce is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Connect with other colleagues in the same hospital or clinic
  • Search all U.S. specialist profiles and refer a patient
  • Read the latest clinical news and earn CME/CEU credits

See Dr. Joyce's full profile

Already have an account?

  • Office

    330 Brookline Ave
    Beth Israel Medical Center
    Boston, MA 02215
    Phone+1 617-667-9920
    Fax+1 617-667-9922
  • Is this information wrong?

Summary

  • Dr. Robin Joyce is an oncologist in Boston, MA and is affiliated with Beth Israel Deaconess Medical Center. She received her medical degree from University of Massachusetts Medical School and has been in practice 25 years. She specializes in hematologic malignancy. She is the director of the clinical lymphoma program. She has expertise in non Hodgkin lymph’s and Hodgkin lymphoma. She also uses cell therapy and transplantation.

Education & Training

  • Harvard Medical School
    Harvard Medical SchoolM.Msc, Clinical Investigation, 1997 - 1998
  • Beth Israel Deaconess Medical Center
    Beth Israel Deaconess Medical CenterFellowship, Hematology and Medical Oncology, 1994 - 1997
  • Dartmouth-Hitchcock/Mary Hitchcock Memorial Hospital
    Dartmouth-Hitchcock/Mary Hitchcock Memorial HospitalResidency, Internal Medicine, 1991 - 1994
  • University of Massachusetts Medical School
    University of Massachusetts Medical SchoolClass of 1991
  • Andover Newton Theological School
    Andover Newton Theological SchoolM.Div, Theology, 1981 - 1984
  • Harvard Medical School
    Harvard Medical SchoolMMS, Clinical Investigation

Certifications & Licensure

  • MA State Medical License
    MA State Medical License 1995 - 2025
  • American Board of Internal Medicine Hematology

Awards, Honors, & Recognition

  • Meaningful Use Stage 1 Certification Centers for Medicare & Medicaid Services, 2011

Clinical Trials

Publications & Presentations

PubMed

Abstracts/Posters

  • Clinical Activity of REGN1979, a Bispecific Human, Anti-CD20 x Anti-CD3 Antibody, in Patients with Relapsed/Refractory (R/R) B-Cell Non-Hodgkin Lymphoma (B-NHL)
    Robin M. Joyce, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
  • Safety and Efficacy of Allogeneic Hematopoietic Stem Cell Transplant after Programmed Cell Death 1 (PD-1) / Programmed Cell Death Ligand 1 (PD-L1) Blockade for Classic...
    Robin M. Joyce, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
  • Development of Novel Second Generation DC/Tumor Fusion Vaccine in Lymphoma
    Robin M. Joyce, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
  • Join now to see all

Lectures

  • PD-1 Blockade with Pembrolizumab for Classical Hodgkin Lymphoma after Autologous Stem Cell Transplantation 
    2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
  • Rituximab/Bendamustine and Rituximab/Cytarabine (RB/RC) Induction Chemotherapy for Transplant-Eligible Patients with Mantle Cell Lymphoma: A Pooled Analysis of Two Pha... 
    2018 ASH Annual Meeting - San Diego, CA - 12/1/2018

Professional Memberships

Hospital Affiliations